

# Evaluation of 19 Autoimmune Disease-associated Loci with Rheumatoid Arthritis in a Colombian Population: Evidence for Replication and Gene-Gene Interaction

HARSHAL A. DESHMUKH, AMIT K. MAITI, XANA R. KIM-HOWARD, ADRIANA ROJAS-VILLARRAGA, JOEL M. GUTHRIDGE, JUAN-MANUEL ANAYA, and SWAPAN K. NATH

**ABSTRACT.** *Objective.* Recent studies have identified several common genes associated with multiple autoimmune diseases that support the hypothesis of the presence of shared or general autoimmunity genes. However, most of this work has been performed in populations of white origin. The main objectives of this study are to replicate the genotype-phenotype correlation between 19 such variants and rheumatoid arthritis (RA), and to evaluate gene-gene interactions between these genes in individuals from an ethnically homogenous nonwhite Colombian population.

*Methods.* Nineteen single-nucleotide polymorphisms (SNP) from 16 genes/loci were genotyped in 353 RA cases and 368 controls. For each SNP, allelic and genotype-based association tests were applied to evaluate genotype-phenotype correlation. Permutation-based tests were used to validate the statistical significance. Gene-gene interactions were assessed by logistic regression.

*Results.* We replicated the genetic association with rs13277113 ( $p = 0.0009$ , OR 1.46) and rs2736340 ( $p = 0.0001$ , OR 1.63) from *C8orf13-BLK* (*8p23.1*, associated with RA and systemic lupus erythematosus), and rs763361 ( $p = 0.03$ ) from *CD226* (*18q22.3*, associated with multiple sclerosis and type 1 diabetes) in the Colombian population. The population-attributable risks were estimated as 27%, 34%, and 16% for rs13277113, rs2736340, and rs763361, respectively. We also detected evidence for gene-gene interaction between SNP in *MMEL1* (rs3890745) and *C8orf13-BLK* (rs13277113;  $p = 0.0002$ ).

*Conclusion.* Our results demonstrate that the *IL2/IL21* region, *C8orf13-BLK*, and *CD226* influence RA in Colombians, and RA shares some of the pathogenic mechanisms associated with other autoimmune diseases. (J Rheumatol First Release July 15 2011; doi:10.3899/jrheum.110199)

## Key Indexing Terms:

RHEUMATOID ARTHRITIS  
GENETIC ASSOCIATION

LATIN AMERICA  
GENE-GENE INTERACTION

From the Genetic Epidemiology Unit, Arthritis and Immunology Research Program, and the Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; and the Center for Autoimmune Diseases Research (CREA), Universidad del Rosario-Corporación para Investigaciones Biológicas, Bogota, Colombia.

Supported by the National Institutes of Health (R01AR060366, R01AI063622, R21AI094377, P20RR020143, P20RR015577, P30AR053483, and U19AI082714); a research grant (HR08-037) from the Oklahoma Center for the Advancement of Science and Technology; and grants from Colciencias (2213-04-16484), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, and the Colombian Association of Rheumatology.

H.A. Deshmukh, MBBS, MPH; A.K. Maiti, PhD; X.R. Kim-Howard, MPH, Genetic Epidemiology Unit, Arthritis and Immunology Research Program, Oklahoma Medical Research Foundation; A. Rojas-Villarraga, MD, CREA, Universidad del Rosario-Corporación para Investigaciones Biológicas; J.M. Guthridge, PhD, Clinical Immunology Research Program, Oklahoma Medical Research Foundation; J.-M. Anaya, MD, CREA, Universidad del Rosario-Corporación para Investigaciones Biológicas; S.K. Nath, PhD, Genetic Epidemiology Unit, Arthritis and Immunology Research Program, Oklahoma Medical Research Foundation.

J.-M. Anaya and S.K. Nath jointly directed this work.

Address correspondence to Dr. S.K. Nath, Genetic Epidemiology Unit, Arthritis and Immunology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA. E-mail: naths@omrf.org

Accepted for publication April 14, 2011.

With the recent surge in genetic research for common complex autoimmune disorders, there is a growing list of susceptibility loci associated with these diseases. Genetic studies of several autoimmune diseases have revealed shared autoimmune susceptibility loci indicating common genetic architecture of some autoimmune diseases, and possible similar underlying disease mechanisms<sup>1,2</sup>. Within families, clustering of distinct autoimmune diseases has been reported, supporting this hypothesis of shared pathogenic factors in autoimmunity. There is a growing list of genes or genomic regions such as *PTPN22*, *CTLA4*, *STAT4*, and *IL12/21* that have shared association with multiple autoimmune diseases. The finding that susceptibility alleles for one disease can be protective for another disease shows the additional level of complexity in the genetics of autoimmune diseases. For example, while the minor allele of the R620W polymorphism in *PTPN22* has been associated with susceptibility to type 1 diabetes, rheumatoid arthritis (RA)<sup>3</sup>, and systemic lupus erythematosus (SLE)<sup>4</sup>, it appears to confer protection to celiac disease<sup>5</sup> and Crohn's disease<sup>6</sup>. Moreover, there are several reports of ethnic-specific genetic associations of autoimmune diseases such as interferon regulatory factor-5<sup>7</sup> and HLA locus<sup>8</sup>, which are

independently associated with autoimmune disease in white populations but not in Asian populations. Investigating these associations in different populations, especially non-European ones, is important and logical not only for their validity but also to understand shared autoimmunity against a specific ethnic/environmental background.

The goals of this study were to assess genotype-phenotype correlation between 19 autoimmune disease-associated variants with RA, and to detect gene-gene interactions in individuals from an ethnically homogenous Colombian population.

## MATERIALS AND METHODS

We examined association between 19 single-nucleotide polymorphisms (SNP) from 16 gene/genomic regions. These loci were chosen from SNP associated with either RA or at least 1 of the 5 other common autoimmune diseases. Of these, 13 were previously reported to be associated with RA (Table 1; *MMEL1*, *CD244*, *KIAA1109*, *IL1/IL2*, *CDK5*, *C8orf13-BLK*,

*PHF19-TRAF1*, *TRAF1-C5*, *DKFZ*, *KIF5A*, *SH2B3*, *C12orf30*, *CD40*), 4 with SLE (*C8orf13-BLK*, *PHF19-TRAF1*, *TRAF1-C5*, *ITGAM*), 7 with type 1 diabetes (*KIAA1109*, *ADAD1*, *IFIH1*, *IL1/IL2*, *CLEC16A*, *CD226*, *SH2B3*), 3 with multiple sclerosis (*IL1/IL2*, *CLEC16A*, *CD226*), and 3 with celiac disease (*KIAA1109*, *IL1/IL2*, *SH2B3*).

We assessed association using a cohort of 353 Colombian patients with RA and 368 healthy controls (543 women, 178 men) enrolled from the Corporación para Investigaciones Biológicas in Medellín. All the study subjects were enrolled at the Center for Autoimmune Diseases Research, in Medellín, and were of Spanish ancestry, originating from the northwestern population of Colombia known as the Paisa community. Historical evidence has documented that individuals from the Paisa community are endogenous, are homogenous, and have very little population stratification<sup>9,10</sup>. Written informed consent was obtained from all individuals before enrollment. The ethics committees of Corporación para Investigaciones Biológicas and Oklahoma Medical Research Foundation approved our study. All Colombian patients with RA were diagnosed and followed up by a single rheumatologist, according to the revised American College of Rheumatology criteria<sup>11</sup>. The average age of onset for patients with RA was 39 (± 12) years.

Table 1. Replication of association in RA samples from Colombia (cases = 353, controls = 368).

SNP	Cyto-position	Gene	Disease	Minor Allele	MAF Case	MAF Control	p	OR (95% CI)	Statistical Power <sup>†</sup>
rs3890745	1p36	MMEL1	RA	C	0.466	0.464	0.959	1.00 (0.80–1.25)	0.42
rs3766379	1q23.3	CD244	RA	T	0.409	0.439	0.279	0.88 (0.70–1.10)	0.41
rs6682654	1q23.3	CD244	RA	G	0.439	0.474	0.247	0.86 (0.68–1.10)	0.42
rs4505848	4q27	KIAA1109	RA, CED, T1D	G	0.376	0.355	0.427	1.09 (0.87–1.38)	0.40
rs17388568	4q27	ADAD1	T1D	A	0.145	0.156	0.570	0.91 (0.68–1.23)	0.26
rs42041	7q21–q22	CDK6	RA	G	0.192	0.200	0.741	0.95 (0.72–1.26)	0.30
rs2736340	8p22–23	C8orf13-BLK	RA, SLE	T	0.468	0.349	0.0001	1.63 (1.27–2.10)	0.39
rs13277113	8p22–23	C8orf13-BLK	SLE	A	0.465	0.373	0.0009	1.46 (1.16–1.82)	0.40
rs881375	9q33	PHF19-TRAF1	RA, SLE	T	0.296	0.313	0.551	0.92 (0.70–1.20)	0.38
rs3761847	9q33	TRAF1-C5	RA, SLE	G	0.391	0.403	0.703	0.95 (0.74–1.22)	0.41
rs4750316	10p15.1	DKFZp667F0711	RA	C	0.120	0.145	0.198	0.80 (0.58–1.11)	0.25
rs1678542	12q13.13	KIF5A	RA	G	0.406	0.439	0.246	0.87 (0.69–1.09)	0.41
rs3184504	12q24	SH2B3	RA, CED	T	0.322	0.322	0.990	0.99 (0.77–1.29)	0.38
rs17696736	12q24.13	C12orf30	RA	G	0.301	0.299	0.932	1.01 (0.79–1.27)	0.37
rs12708716	16p13.13	CLEC16A	MS, T1D	G	0.288	0.316	0.263	0.87 (0.69–1.10)	0.38
rs1143679	16p11.2	ITGAM	SLE	A	0.121	0.107	0.450	1.14 (0.80–1.63)	0.20
rs763361	18q22.3	CD226	MS, T1D	T	0.440	0.393	0.122	1.21 (0.94–1.54)	0.41
rs4810485	20q12–q13	CD40	RA	T	0.203	0.206	0.882	0.97 (0.74–1.28)	0.31

<sup>†</sup> Statistical power calculated for  $\alpha = 0.05$ , OR = 1.2, given sample size and control minor allele frequency for each SNP. RA: rheumatoid arthritis; SNP: single-nucleotide polymorphism; T1D: type 1 diabetes; SLE: systemic lupus erythematosus; CED: celiac disease; MS: multiple sclerosis; MAF: minor allele frequency.

Genotyping was performed using Taqman SNP genotyping assay in both ABI 7300 and 7500 instruments (Applied Biosystems, Foster City, CA, USA). Polymerase chain reactions were carried out in a total reaction volume of 20  $\mu$ l, containing 15 ng genomic DNA as a template, 10  $\mu$ l of Taqman genotyping master media, 0.5  $\mu$ l of 40 $\times$  assay mix, and ddH<sub>2</sub>O up to 20  $\mu$ l of final volume.

Statistical analyses were performed with PLINK<sup>12</sup> and Haploview<sup>13</sup>. All SNP were tested for Hardy-Weinberg equilibrium (HWE) in cases and controls separately. Significant differences of allele and genotypic distributions were analyzed using 2-tailed chi-squared tests. To assess the robustness of this significance we performed 100,000 permutation tests. P values, OR, and 95% CI were calculated using Fisher's exact tests and logistic regression analysis. Power calculations were performed with the genetic power calculator implemented in CATS<sup>14</sup> using a multiplicative model under varying disease allele frequencies (5% to 40%) and genotype relative risks (1.1 to 1.8). Population-attributable risk (PAR) was calculated as  $PAR = (X - 1)/X$ . Assuming a multiplicative model,  $X = (1 - f)^2 + 2f(1 - f)\gamma + f^2\gamma^2$ , where  $\gamma$  is the estimated OR and  $f$  is the frequency of risk allele<sup>15</sup>.

Gene-gene interactions were assessed using SNPAssoc<sup>16</sup>. To adjust for multiple testing we used both Bonferroni corrections and false discovery rate (FDR). For 153 pairwise interactions from 18 SNP with a 5% type-1 error, Bonferroni corrections suggested a threshold of  $p > 0.0003$ . We used FDR at a level of 5% (q value, a measure of significance) to adjust p values according to the number of hypotheses tested<sup>17</sup>. A q value < 0.05 is considered significant.

## RESULTS

The minor allele frequency (MAF) for each SNP is shown in Table 1. All SNP were in Hardy-Weinberg equilibrium in cases and controls except the loci at 10p15, rs12251307 ( $p_{HWE} = 2.62 \times 10^{-6}$  in cases and  $1.71 \times 10^{-10}$  in controls), which was excluded from further analysis. Our power analysis demonstrated that these samples have more than 80% power to detect an OR of 1.4 for a MAF threshold at 20% or more (using a multiplicative model, at the 5% significance level). We performed a model-based association test for each of the 18 SNP.

We found that both rs13277113 [ $p = 0.0009$ ; OR 1.46 (95% CI 1.16–1.82)] and rs2736340 [ $p = 0.0001$ ; OR 1.63 (95% CI 1.27–2.10)], located near the 5' ends of *BLK* and *C8ORF13*, were significantly associated. The MAF for rs2736340 ("T") and rs13277113 ("A") was 47% and 46% in cases, and 35% and 37% in controls, respectively. Notably, the MAF for rs13277113 and rs2736340 is much higher in Colombian controls than reported in European-American populations in HapMap data (both ~25% for both alleles). These 2 SNP were in high linkage disequilibrium (LD;  $r^2 = 87\%$ ) in both cases and controls. Haplotype-based association testing for these SNP showed significant association (global  $p = 0.00018$ ), with a higher frequency of "TA" haplotype in cases as compared to controls [44% vs 33%;  $p = 0.0001$ , OR 1.40 (95% CI 1.12–1.75)]. Using conditional analysis, neither SNP could independently explain the global p value, which was not surprising given the high LD between these SNP.

We also assessed the association at each SNP between patients who were anti-cyclic citrullinated peptide (CCP) antibody-positive (data were available for 126 patients) and controls. Despite the low power (data not shown) for these analy-

ses, rs2736340 was the only SNP that showed significant association ( $p = 0.04$ ) in this subgroup analysis with anti-CCP antibody-positive patients.

To explore gene-gene interaction, we assessed all pairwise gene-gene interactions using SNPAssoc. The 2 notable pairwise interactions are shown under different models in Table 2. First, an interaction was detected between *MMEL1* and *C8orf13-BLK* under codominant ( $p = 0.006$ ), dominant ( $p = 0.01$ ), and log-additive ( $p = 0.0002$ ) models. The second interaction was detected between *CD244* and *CDK6* under a codominant model ( $p = 0.007$ ), dominant model ( $p = 0.09$ ), and log-additive model ( $p = 0.01$ ). To correct for multiple testing, we evaluated all pairwise interactions by both Bonferroni corrections and FDR. The interaction p value for *MMEL1*  $\times$  *C8orf13-BLK* under the log-additive model ( $p = 0.0002$ ) showed borderline significance after correction for multiple testing using both corrections (p value cutoff = 0.00026) and FDR calculation (q value = 0.06). However, the interaction p value for *CD244* and *CDK6* was not significant after correction for multiple tests.

## DISCUSSION

Recent genome-wide association analyses (GWAS) have implicated several genes associated with RA, and some of these genes have also been shown to be associated with other autoimmune diseases, or vice versa. While the identification of the precise pathways involved in susceptibility to autoimmune diseases will clearly require additional time and effort, integration of data from multiple diseases represents the logical next step in discovering similarities and differences among them. Since these regions of shared autoimmunity are consistently reported from European-derived populations, it is important to confirm these known associations in non-European populations under different geocultural environments.

The 2 associated SNP were located in the *C8orf13-BLK* region. These SNP were first shown to be associated with SLE in a GWAS, and then replicated in Chinese and Japanese<sup>7</sup> populations. Recently, 2 studies showed association of SNP from *C8orf13-BLK* region with RA in a European population. First, a study<sup>18</sup> reported an association between rs2736340 and RA in a European population ( $p = 5.69 \times 10^{-9}$ , OR 1.19) with a MAF (allele "T") of 28% in cases vs 24% in controls, and a PAR of 9%. Second, our recent analysis of the data of the North American Rheumatoid Arthritis Consortium (Genetic Analysis Workshop 16 RA) showed significant association of both rs2736340 ( $p = 1.45 \times 10^{-5}$ , OR 1.36) and rs13277113 ( $p = 3.46 \times 10^{-6}$ , OR 1.39) with RA. The PAR was estimated at about 14% and 15%, respectively<sup>2</sup>. Of note, Ito, *et al*<sup>19</sup> recently reported a PAR of 9.2% in a white population; for a Japanese population it was 22% for *BLK*. Another study<sup>20</sup> attempted to replicate recently identified SLE-associated variants in RA samples with European origin. Although they did not replicate association with any of the SNP with RA, they

Table 2. Prominent gene-gene interaction between rheumatoid arthritis susceptibility genes. Pairwise interactions among 18 single-nucleotide polymorphisms (SNP) tested under different models using the SNPassoc tool for assessing gene-gene interactions.

Gene1 (SNP A) × Gene2 (SNP B)	Log-additive	SNPassoc			PLINK	
		Dominant	Recessive	Codominant	Log-additive	q-value*
MMEL1 (rs3890745) × C8orf13BLK(rs13277113)	0.0002	0.01	0.02	0.006	0.00037	0.06
CD244 (rs3766379) × CDK6 (rs42041)	0.01	0.09	0.01	0.007	0.01	0.53

\* q-value is a measure of significance after correction for multiple testing using false discovery rate, at  $\alpha = 5\%$ ; q-value < 0.05 is considered statistically significant. PLINK: genome analysis tool.

showed association between rs13277113 and a subgroup of patients with RA who had Sjögren's syndrome ( $p = 5 \times 10^{-4}$ ). Although functional significance for these SNP remains to be extensively established, reduced expression of *BLK* has been observed with the risk allele, and detailed mechanisms of this reduced expression are not yet known. It is also possible that these 2 SNP in the 5' end of the *BLK* gene may bind transcription factors differentially compared to opposite allele and modulate expression.

We also replicated the association of rs763361 from *CD226* (*18q22.3*) in this Colombian population under the dominant model ( $p = 0.03$ ). The rs763361 SNP has been shown to be associated with multiple autoimmune disorders<sup>21</sup> (Table 1) and is an interesting candidate for general autoimmunity. None of the remaining 15 loci was replicated in this Colombian sample. There could be several reasons for this. First, lack of replication of other loci could be due to clinical and genetic heterogeneity of patients with RA, or it could be because of a population-specific effect. Second, it is possible that some of these markers are not the actual predisposing variants, but variants that are in high LD with predisposing variants. A varying LD pattern between Colombian and white populations would be expected. Therefore, without the proper haplotype "tagged" SNP, detecting disease-predisposing SNP may not be possible. A detailed, dense genotyping and association analysis is required to resolve these issues. Third, it is also possible that our study lacked sufficient power to detect modest associations. While we may have had sufficient power to detect a larger effect size (i.e.,  $OR \geq 1.6$ ), our sample size was underpowered to detect association when  $OR \leq 1.2$  (Table 1). Indeed, most of the susceptibility genes detected through GWAS have more modest effects around that range and require a larger sample. For example, *CD40* was identified as a novel RA susceptibility gene only after the meta-analysis involving 7322 cases and 18,207 controls<sup>3,22</sup>.

We detected evidence of interaction between *MMEL1-C8orf13* and *BLK* regions that retained significance after both Bonferroni correction and FDR. We also detected suggestive evidence for interaction between *CD244* (rs3766379) and

*CDK6* (rs42041) under dominant, codominant, and log-additive models (Table 2). This was not significant after correction for multiple testing, although possible interactions could not be ruled out. Both these SNP have been described to be associated with RA<sup>3,23,24</sup>. It is important to note that with our sample size we had a modest power to assess gene-gene interaction. For example, using the genetic power calculator for gene-gene interaction (QUANTO), we assessed that with a disease prevalence of about 1%, and level of significance  $\alpha = 0.0002$ , using a log-additive model we had about 7% power to detect interaction between *CD244* and *CDK6* and about 20% power to detect interaction between *MMEL1* and *C8orf13-BLK*. Extensive search of the microRNA database shows rs3890745 of *MMEL1* indicate that this intronic SNP gives very high homology (data not shown) with mature miRNA of various mammals and with humans (hsa-miR-544). We could speculate that this SNP-carrying sequence could code a miRNA that differentially interacts in the promoter region of *BLK* (rs13277113 carrying alternative allelic sequences) and modulates the expression of the *BLK* gene.

However, we acknowledge that the gene-gene interaction we observed is not a confirmative but provides a suggestive indication only. Therefore, even in this homogenous population, it is necessary to further evaluate these interactions in another population. Nevertheless, these analyses provide the basis for testing interactions in larger sample sizes of other ethnic groups.

We replicated the association with 3 SNP for RA in a Colombian population and reported evidence of possible interaction between 2 susceptibility genes (*MMEL1-C8orf13-BLK*) for the first time. These genes are now members of the growing list of confirmed genes with relatively common polymorphisms that have been implicated in the predisposition to multiple autoimmune diseases<sup>3</sup>. Contributions of these genes to disease predisposition in RA clearly indicated common disease mechanisms between RA and other autoimmune disorders. This information may help us to understand the underlying genetic mechanisms of autoimmunity and may help to identify future molecular targets for disease diagnosis and therapy.

## ACKNOWLEDGMENT

We thank the patients and their families for their cooperation. We also thank Ms. Parvathi Viswanathan for her help in genotyping the SNP.

## REFERENCES

1. Anaya JM, Gomez L, Castiblanco J. Is there a common genetic basis for autoimmune diseases? *Clin Dev Immunol* 2006;13:185-95.
2. Deshmukh H, Kim-Howard X, Nath SK. Replication of recently identified associated single-nucleotide polymorphisms from six autoimmune diseases in Genetic Analysis Workshop 16 rheumatoid arthritis data. *BMC Proc* 2009;3 Suppl 7:S31.
3. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burt NP, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. *Nat Genet* 2008;40:1216-23.
4. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PTK, KIAA1542 and other loci. *Nat Genet* 2008;40:204-10.
5. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet* 2008;40:955-62.
6. Wang K, Baldassano R, Zhang H, Qu HQ, Imielinski M, Kugathasan S, et al. Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. *Hum Mol Genet* 2010;19:2059-67.
7. Shin HD, Kim I, Choi CB, Lee SO, Lee HW, Bae SC. Different genetic effects of interferon regulatory factor 5 (IRF5) polymorphisms on systemic lupus erythematosus in a Korean population. *J Rheumatol* 2008;35:2148-51.
8. Plenge RM. Rheumatoid arthritis genetics: 2009 update. *Curr Rheumatol Rep* 2009;11:351-6.
9. Pineda-Trujillo N, Carvajal-Carmona LG, Buritica O, Moreno S, Uribe C, Pineda D, et al. A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia. *Neurosci Lett* 2001;298:87-90.
10. Bravo ML, Valenzuela CY, Arcos-Burgos OM. Polymorphisms and phyletic relationships of the Paisa community from Antioquia (Colombia). *Gene Geogr* 1996;10:11-7.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
12. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559-75.
13. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263-5.
14. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat Genet* 2006;38:209-13.
15. Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, van Dam RM, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. *Diabetes* 2006;55:2645-8.
16. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, et al. SNPAssoc: an R package to perform whole genome association studies. *Bioinformatics* 2007;23:644-5.
17. Storey JD, Tibshirani R. Statistical significance for genomewide studies. *Proc Natl Acad Sci USA* 2003;100:9440-5.
18. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, et al. REL, encoding a member of the NF-kB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat Genet* 2009;41:820-3.
19. Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Kawamoto M, et al. Association of the FAM167A-BLK region with systemic sclerosis. *Arthritis Rheum* 2010;62:890-5.
20. Suarez-Gestal M, Calaza M, Dieguez-Gonzalez R, Perez-Pampin E, Pablos JL, Navarro F, et al. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. *Arthritis Rheum* 2009;60:2558-64.
21. Maiti AK, Kim-Howard X, Viswanathan P, Guillen L, Qian X, Rojas-Villarraga A, et al. Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases. *Rheumatology* 2010;49:1239-44.
22. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet* 2010;42:508-14.
23. van der Linden MP, Feitsma AL, le Cessie S, Kern M, Olsson LM, Raychaudhuri S, et al. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. *Arthritis Rheum* 2009;60:2242-7.
24. Orozco G, Eyre S, Hinks A, Ke X; Wellcome Trust Case Control consortium YEAR Consortium, Wilson AG, Bax DE, et al. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. *Ann Rheum Dis* 2010;69:813-6.